IDEXX Laboratories said gross profit for Q3 2025 increased due to higher revenue and a 70 basis points increase in gross profit margin. The company said the increase in gross profit margin reflected benefits from higher volumes in IDEXX VetLab consumables and Reference Lab testing, along with operational productivity and pricing benefits, which offset inflationary cost effects. It added that these increases in gross profit margin were reduced by the business mix impact from higher instrument revenue.

1. 01

   IDEXX Laboratories said gross profit for Q3 2025 increased due to higher revenue and a 70 basis points increase in gross profit margin. The company said the increase in gross profit margin reflected benefits from higher volumes in IDEXX VetLab consumables and Reference Lab testing, along with operational productivity and pricing benefits, which offset inflationary cost effects. It added that these increases in gross profit margin were reduced by the business mix impact from higher instrument revenue.

2. 02

   IDEXX Laboratories said cash provided by operating activities for the 9 months ended September 30, 2025 was $826.0 million, a net increase of $159.1 million compared to the same period during the prior year. The company said cash was provided from net income of $811.3 million, adjusted for net non-cash items of $259.3 million, partially offset by a net decrease from changes in operating assets and liabilities of $244.5 million.

3. 03

   IDEXX Laboratories said cash used by financing activities for the 9 months ended September 30, 2025 was $809.3 million, compared to $645.3 million in the same period during the prior year. The company cited repurchases of common stock of $979.2 million, compared to $591.0 million in the prior year, and repayment of 2025 Series C Notes of $103.4 million as factors increasing cash used, partially offset by net borrowings under the Credit Facility of $205.0 million.

4. 04

   IDEXX Laboratories said as of September 30, 2025, outstanding borrowings under the Credit Facility were $455.0 million, of which $250.0 million was a term loan maturing on October 20, 2025. The company said it repaid this term loan on October 20, 2025 using borrowings under the revolving line of credit and cash on hand.

Key figures

Quarter ended September 30, 2025

Revenue

$1.1B

Operating income

$355M

Net income

$275M

EPS

$3.40

Gross profit

$683M

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.